This Slide: #9 of 83 |
Slide #9. Charles River Laboratories — CRO Services Division of Galapagos NV
Acquirer:
Charles River Laboratories (NYSE:CRL)
Acquiree:
CRO Services Division of Galapagos NV
Details:
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has completed the previously announced acquisition of the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. The acquisition positions Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.
Charles River Laboratories International is a full service, non-clinical global drug development partner. Co. has laboratory animal medicine and science (research model technologies) to develop a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports its clients from target identification through non-clinical development. Co. also provides a suite of products and services to support its clients' manufacturing activities, including its contract development and manufacturing organization business. Co. has three reporting segments: Research Models and Services, Discovery and Safety Assessment and Manufacturing Solutions.
CRL SEC Filing Email Alerts Service
Open the CRL Page at The Online Investor »
|
Open the CRL Page at The Online Investor (in a new window) »
Free CRL Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (3.20 out of 4) 40th percentile
(ranked lower than approx. 60% of all stocks covered)
Analysts' Target Price: CRL Stock Forecast Based on Zacks ABR data; powered by Xignite |